Pregabalin

1. 2026-10-19issueIssued info_card
2. 2026-09-24srcPregabalin for neuropathic pain in adults.
3. 2026-09-24srcPregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial.
4. 2026-09-24srcGabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
5. 2026-09-24srcPregabalin withdrawal in patients without psychiatric disorders taking a regular dose of pregabalin: A case series and literature review.
6. 2026-09-24srcPathophysiological Roles of Auxiliary Calcium Channel Alpha2delta Subunits.
7. 2026-09-24srcPregabalin abuse and dependence in Germany: results from a database query.
8. 2026-09-24srcNeuronal alpha2delta proteins and brain disorders.
9. 2026-09-24srcMolecular and hormonal changes caused by long-term use of high dose pregabalin on testicular tissue: the role of p38 MAPK, oxidative stress and apoptosis.
10. 2026-09-24srcEffects of Gabapentin and Pregabalin on Calcium Homeostasis: Implications for Physical Rehabilitation of Musculoskeletal Tissues.
11. 2026-09-24srcMisuse and abuse of pregabalin and gabapentin: cause for concern?
12. 2026-09-24srcPregabalin: a review of its use in adults with generalized anxiety disorder.
13. 2026-09-24srcA Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.
14. 2026-09-24srcTrends in gabapentinoid prescribing, co-prescribing of opioids and benzodiazepines, and associated deaths in Scotland.
15. 2026-09-24srcPharmacokinetics of a New, Once-Daily, Sustained-release Pregabalin Tablet in Healthy Male Volunteers.
16. 2026-09-24srcThe calcium channel agonist (±)-BAY-K-8644 attenuates the ability of gabapentinoids to increase the potency of fentanyl and heroin and decrease the potency of cocaine and d-methamphetamine.
17. 2026-09-24srcTrends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study.
18. 2026-09-24srcFatal pregabalin poisoning in Japan: A case report.
19. 2026-09-24srcEfficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
20. 2026-09-24srcPharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis.
21. 2026-09-24srcSexual Dysfunctions Induced by Pregabalin.
22. 2026-09-24srcRisk to heroin users of polydrug use of pregabalin or gabapentin
23. 2026-09-24srcAnalgesia with Gabapentin and Pregabalin May Involve N-Methyl-d-Aspartate Receptors, Neurexins, and Thrombospondins.
24. 2026-09-24srcGabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels.
25. 2026-09-24srcBenefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials.
26. 2026-09-24srcPregabalin use early in pregnancy and the risk of major congenital malformations.
27. 2026-09-24srcA meta-epidemiological study on the reported treatment effect of pregabalin in neuropathic pain trials over time.
28. 2026-09-24srcThe increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin.
29. 2026-09-24srcPregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.
30. 2026-09-24srcComparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis.
31. 2026-09-24srcGabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.
32. 2026-09-24srcEpinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications.
33. 2026-09-24srcPregabalin abuse and dependence during insomnia and protocol for short-term withdrawal management with diazepam.
34. 2026-09-24srcPharmacokinetics of pregabalin in subjects with various degrees of renal function.
35. 2026-09-24srcEfficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
36. 2026-09-24srcPregabalin pharmacology and its relevance to clinical practice.
37. 2026-09-24srcPlacement of pregabalin into Schedule V. Final rule
38. 2026-09-24srcAlpha2delta subunit voltage-gated calcium channel ligands: Ki values and anti-allodynic effects comparison.
39. 2026-09-24srcPregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis.
40. 2026-09-24srcPregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.
41. 2026-09-24srcReclassification of pregabalin and gabapentin to Schedule 3 drugs from 1 April 2019
42. 2026-09-24srcPregabalin (Lyrica) FDA Approval History
43. 2026-09-04issueIssued emergency
44. 2026-09-04issueIssued info_card
45. 2026-09-04issueIssued notice
46. 2026-07-03proposaldependence · taper
47. 2026-06-04proposal29 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
48. 2026-06-04publicationPublication — backfill
49. 2026-04-28revisionRevision 1
50. 2026-04-28genGeneration — pipeline-v5 · with 2 morepipeline-v5
51. 2026-04-28rungeneration run

The same entries, as forms: six forms.